Published in Biotech Business Week, November 24th, 2008
The substantial growth in profitability of the Group could be attributed mainly to the increase in revenue and improvement in gross margin. For the 9 months ended 30 September 2008, the gross margin for the period under review stood at 70.6%, up by 1.4 percentage points over the same period last year, despite an unfavorable exchange rate for the licensed products. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.